

Massive Transfusion Consensus Conference

Day 1 Thursday, June 9, 2011

1300 Welcome, Opening Remarks and Introductions - *Dr. Sandro Rizoli*

Session 1 - Introduction - *Dr. Sandro Rizoli, Moderator*

1315 Epidemiology of civilian trauma in Canada - *Dr. Carolyn Snider*

1335 Early trauma-associated coagulopathy versus dilutional coagulopathy - *Dr. Karim Brohi*

1410 Can we identify trauma patients at risk for massive transfusion based on baseline characteristics? - *Dr. Bryan Cotton*

1445 Q&A Discussion

1500 Break

Session 2 - *Dr. Homer Tien, Moderator*

1515 What are the practical limitations of Massive Transfusion Protocols? - *Dr. Gwen Clarke*

1535 Q&A Discussion

Session 3 - The usefulness of laboratory tests for the management of massively bleeding patients - *Dr. Katerina Pavenski, Moderator*

1550 What do coagulation laboratory tests help (or not help) in massively bleeding patients? - *Dr. Mark Crowther*

1610 What does ROTEM® add to the management of massive hemorrhage? - *Dr. Herbert Schoechl*

1630 What are the strategies to reduce turn-around-time for laboratory results to allow for 'goal-directed' resuscitation? - *Dr. Wayne Chandler*

1650 Q&A Discussion and Adjournment

1730 Panel Deliberation Session (Closed)

Day 2 Friday, June 10, 2011

Session 4 - Is there sufficient published evidence to justify 1:1:1 formula driven resuscitation as the standard of care for bleeding trauma patients? -

Mr. David Howe, Moderator

0800 Summary of the evidence supporting 1:1:1 formula-driven resuscitation in civilian trauma patients - *Dr. Philip Spinella*

0830 To what extent is the evidence on 1:1:1 formula-driven resuscitation affected by survivorship bias? - *Dr. Christopher Snyder*

0845 A critical appraisal of the content of the massive transfusion protocol trials. Is the evidence adequate to support changes on the standard of care? - *Dr. Ryan Zarychanski*

0900 A critical appraisal of the methodology of the 1:1:1 trials. Is the evidence on 1:1:1 formula-driven resuscitation adequate to support its adoption as standard of care in Canada? - *Dr. Damon Scales*

0930 Q&A Discussion

0950 Break

Session 5 - In addition to plasma, is there a role for other blood components and products in the resuscitation of massively bleeding patients? -

Dr. Catherine Moltzan, Moderator

In the setting of massive hemorrhage, what is the role for 'goal-directed' or 'formula-driven'...

1015 Tranexamic Acid (CRASH 2)? - *Dr. Ian Roberts (video)*

1030 Fibrinogen concentrate and factor XIII? - *Dr. Herbert Schoechl*

1045 Cryoprecipitate and Platelet transfusion? - *Dr. Harry Stinger*

1110 Fibrinogen use? - *Dr. Samuel Tisherman*

1125 Prothrombin complex and recombinant factor VIIa? - *Dr. Yulia Lin*

1140 Q&A Discussion

12noon Lunch

Session 6—Collateral damage : What is the harm and cost of 1:1:1 formula driven? - *Dr. Bartolomeu Nascimento, Moderator*

1300 Risk - benefit: Is there evidence to suggest that formula driven resuscitation may harm patients transfused less than 10 units of RBC? - *Dr. Kenji Inaba*

1325 Cost - effectiveness: What is the cost associated with 1:1:1 formula-driven resuscitation? - *Dr. Jeffrey Hoch*

1345 Q&A Discussion

Session 7 - Going beyond trauma: What is the level of evidence and biological rationale supporting the adoption of 1:1:1 formula driven resuscitation

in... - *Dr. Lucinda Whitman, Moderator*

1405 Cardiac surgery? - *Dr. Gurmeet Singh*

1420 Other specialties? - *Dr. Katerina Pavenski*

1435 Q&A Discussion

Session 3 (continued from June 9th) - *Dr. Lucinda Whitman, Moderator*

1445 What does TEG® add to the management of massive hemorrhage? - *Dr. JL Kashuk (via videoconference)*

1510 Q&A Discussion and Adjournment

1520 Break

1530 Panel Deliberation Session (Closed)

Day 3 Saturday, June 10, 2011

Session 8 - *Dr. Sandro Rizoli, Moderator*

0815 Future Studies - *Dr. Bartolomeu Nascimento*

0845 Q&A Discussion

0900 Presentation of draft consensus statement - *Dr. Sunny (Walter) Dzik*

0945 Speaker feedback and comments

1015 Break

1045 Open discussion

1230 Closing remarks - *Dr. Sandro Rizoli*